Gout vs. Calcium Pyrophosphate Deposition Disease (CPPD) aka. pseudogout

Gout and Calcium Pyrophosphate Deposition Disease (CPPD), also known as pseudogout, are two forms of crystal-induced arthritis that share similar clinical features but differ in their underlying causes, crystal composition, and radiological findings. Understanding these differences is critical for accurate diagnosis and effective treatment.

---

1. Cause and Pathophysiology

• Gout is caused by the deposition of monosodium urate crystals in the joints due to hyperuricemia (elevated uric acid levels). These crystals trigger an intense inflammatory response, leading to acute episodes of joint pain and swelling.
• CPPD (Pseudogout) results from the deposition of calcium pyrophosphate dihydrate (CPP) crystals in the joint cartilage. These crystals also cause inflammation, but the mechanism is less related to systemic metabolic disturbances like hyperuricemia.

---

2. Crystal Characteristics

• Gout (Monosodium Urate Crystals): These needle-shaped crystals exhibit strong negative birefringence. Under polarized light, they appear yellow when aligned parallel to the slow axis and blue when aligned perpendicular.
• CPPD (Calcium Pyrophosphate Crystals): These rhomboid-shaped crystals show weak positive birefringence. Under polarized light, they appear blue when aligned parallel to the slow axis and yellow when aligned perpendicular.

---

3. Clinical Presentation

• Gout typically presents with acute, intense pain in the joints, most commonly the big toe (first metatarsophalangeal joint). The affected joint is often red, swollen, and hot to the touch. Gout is strongly associated with hyperuricemia and may be triggered by factors like alcohol consumption or certain foods.
• CPPD (Pseudogout) often affects larger joints, particularly the knees and wrists, with pain and swelling that may be less dramatic than in gout. Importantly, the affected joint may not appear red or hot. CPPD is commonly seen in older adults and is associated with conditions like osteoarthritis and metabolic disorders.

---

4. Radiographic Findings (X-ray)

• Gout: Chronic cases of gout may show erosions or "punched-out" lesions in the bone near the affected joints. However, early stages of gout often do not present with visible changes on X-ray.
• CPPD (Pseudogout): A key radiographic finding in CPPD is chondrocalcinosis, which refers to the calcification of cartilage. On X-ray, chondrocalcinosis appears as linear calcifications within the joint cartilage, particularly in the meniscus of the knee or triangular fibrocartilage of the wrist. Degenerative changes in the joint, such as joint space narrowing and osteophyte formation, may also be present.

---

5. Diagnosis

• Gout is diagnosed based on clinical presentation, elevated serum uric acid levels, and the identification of monosodium urate crystals in joint fluid under polarized light microscopy.
• CPPD (Pseudogout) is diagnosed by identifying calcium pyrophosphate crystals in joint fluid and by the presence of chondrocalcinosis on X-ray. Serum calcium and magnesium levels may also be tested to rule out underlying metabolic conditions.

---

6. Management

• Gout: Acute attacks are treated with NSAIDs, colchicine, or corticosteroids. Long-term management focuses on reducing uric acid levels using allopurinol or febuxostat and lifestyle modifications to avoid triggers.
• CPPD (Pseudogout): Acute treatment is similar to gout, using NSAIDs, colchicine, or corticosteroids to reduce inflammation. There is no definitive long-term treatment for CPPD, but managing any underlying conditions such as osteoarthritis or metabolic imbalances is important.

---

Gouty Arthritis Management

1. Acute Gout Flare Management

• First-Line Medications:
  • NSAIDs:
    • Examples: Naproxen (500 mg twice daily), indomethacin (50 mg three times daily), or ibuprofen (800 mg three times daily).
    • Duration: Continue until symptoms resolve (typically within 5-7 days).
    • Precautions: Avoid in patients with renal impairment, peptic ulcer disease, or uncontrolled hypertension.
  • Colchicine:
    • Dosing: 1.2 mg initially, followed by 0.6 mg an hour later (total 1.8 mg for the first day). Maintenance dose: 0.6 mg once or twice daily as needed.
    • Considerations: Reduce dose in renal impairment or if the patient is on drugs that inhibit CYP3A4.
  • Corticosteroids:
    • Oral: Prednisone 30-40 mg daily for 5-7 days with a gradual taper.
    • Intra-articular: Triamcinolone for monoarticular flares (dose based on joint size).
• Adjunctive Measures:
  • Cold Compresses: Apply to affected joints to reduce inflammation and pain.
  • Analgesics: Acetaminophen can be added if pain persists.

2. Long-Term Management of Gout

• When to Initiate Uric Acid-Lowering Therapy (ULT):
  • Indicated for patients with frequent gout attacks (≥2 per year), tophi, chronic kidney disease (stage 2 or higher), or urate nephrolithiasis.
  • Timing: ULT should be started once the acute flare has resolved, as initiating therapy during a flare may worsen symptoms.
• Uric Acid-Lowering Therapy Options:
  • Allopurinol:
    • Starting Dose: To avoid hypersensitivity reactions, begin at 100 mg daily (50 mg in patients with severe renal impairment).
    • Titration: Increase by 100 mg every 2-5 weeks to reach the target uric acid level (≤6 mg/dL; ≤5 mg/dL if tophi are present).
    • Max Dose: Can go up to 800 mg daily as tolerated and needed to reach target levels.
    • Monitoring: Check uric acid and renal function every 2-4 weeks during titration, then every 3-6 months.
  • Febuxostat: Alternative to allopurinol, often for those who cannot tolerate allopurinol or who are HLA-B*5801 positive.
    • Start at 40 mg daily, increasing to 80 mg daily if needed.
  • Uricosuric Agents (e.g., Probenecid):
    • Useful for patients who cannot tolerate xanthine oxidase inhibitors.
    • Precaution: Requires good kidney function and adequate hydration to prevent kidney stones.
• Prophylaxis During ULT Initiation:
  • Use low-dose colchicine (0.6 mg once or twice daily) or an NSAID for 3-6 months when initiating ULT to prevent gout flares.
• Lifestyle and Dietary Modifications:
  • Reduce Purine Intake: Avoid high-purine foods like red meat, shellfish, and organ meats.
  • Limit Alcohol and Sugary Beverages: Particularly avoid beer and spirits.
  • Hydration: Encourage adequate fluid intake to reduce kidney stone risk.
  • Weight Management: Achieve and maintain a healthy weight to reduce uric acid levels and prevent attacks.

Calcium Pyrophosphate Deposition (CPPD) Arthritis Management

1. Acute CPPD Arthritis (Pseudogout) Flare Management

• First-Line Medications:
  • NSAIDs:
    • Similar dosing and precautions as used in gout (e.g., naproxen 500 mg twice daily).
    • Duration: Typically for 5-7 days or until symptoms resolve.
  • Colchicine:
    • Dosing: Same as in gout for acute management (1.2 mg initially, followed by 0.6 mg after an hour).
    • Prophylactic Dosing: 0.6 mg once or twice daily may be helpful in recurrent CPPD.
  • Corticosteroids:
    • Oral: Prednisone 30-40 mg daily, tapered over 5-7 days.
    • Intra-articular: Triamcinolone for localized joint involvement (dosage based on joint size).
• Adjunctive Measures:
  • Cold Compresses: Applied to the affected joint for pain relief.
  • Analgesics: Acetaminophen can be added if additional pain relief is needed.

2. Long-Term Management of CPPD Arthritis

• Chronic and Recurrent Pseudogout:
  • Colchicine Prophylaxis: 0.6 mg daily or twice daily may help prevent recurrent flares.
  • NSAID Prophylaxis: Consider in patients who tolerate NSAIDs well and have frequent flares.
  • Physical Therapy: For chronic CPPD, especially in joints affected by osteoarthritis-like changes, to improve function and prevent stiffness.
• Managing Associated Conditions:
  • Screen and manage underlying conditions that may contribute to CPPD deposition:
    • Hyperparathyroidism
    • Hypomagnesemia
    • Hemochromatosis
    • Hypophosphatasia
• Imaging Monitoring:
  • X-ray Follow-up: Evaluate for progression of chondrocalcinosis, which is a hallmark of CPPD and may guide adjustments in management.
• Patient Education and Lifestyle Modifications:
  • Diet and Hydration: Encourage a balanced diet with adequate hydration.
  • Weight Management: For patients with osteoarthritis-like symptoms, weight management may improve joint function.
  • Avoid Joint Trauma: To prevent further joint damage, advise on protecting affected joints.

Summary of Differentiated Management for Gout and CPPD Arthritis

Patient Education

• Gout: Emphasize adherence to ULT, lifestyle changes, and potential flare prevention.
• CPPD: Educate on joint protection, symptom management, and the role of physical therapy for joint health.

---

Conclusion

While both gout and CPPD involve crystal deposition in joints and can present similarly with joint pain and inflammation, they differ significantly in terms of crystal type, clinical presentation, and management. Gout is associated with monosodium urate crystals, strong negative birefringence, and often a red, hot joint, while CPPD involves calcium pyrophosphate crystals, weak positive birefringence, and the characteristic radiographic finding of chondrocalcinosis. Proper differentiation between the two conditions is essential for guiding appropriate treatment strategies.